Johnson & Johnson filed to dismiss a US patent infringement lawsuit related to Impax's generic version of Concerta (methylphenidate), the generic drugmaker announced Tuesday. Johnson & Johnson indicated that it will instead pursue a Citizen's Petition with the FDA regarding approval criteria for generic versions of the attention-deficit hyperactivity disorder drug, Bloomberg reports.
Impax noted in a statement that its generic version of Concerta is currently under review by the FDA. The drug had US sales of $846 million in the twelve month-period ended in July.
Meanwhile, a spokesperson for Johnson & Johnson said that the drugmaker has not abandoned a similar patent infringement suit that has been filed against Andrx, in an effort to block generic competition for Concerta until 2018, Bloomberg reports.
To read more Top Story articles, click here.